Literature DB >> 11514498

Fulminant eosinophilic endomyocarditis in an asthmatic patient treated with pranlukast after corticosteroid withdrawal.

S Hayashi1, S Furuya, H Imamura.   

Abstract

Several cases of eosinophilic conditions including Churg-Strauss syndrome have been reported in association with the use of cysteinyl leukotriene receptor antagonists, including zafirlukast, montelukast, and pranlukast, in asthmatic patients. The case of a 26 year old woman with a three year history of asthma, rhinitis, and nasal polyps is reported in whom eosinophilia, pulmonary infiltrates, and fulminant eosinophilic endomyocarditis accompanied by cardiogenic shock developed during pranlukast treatment after corticosteroid withdrawal. Acute necrotising eosinophilic endomyocarditis was confirmed by endomyocardial biopsy. The patient recovered after intensive treatment, including mechanical assistance involving intra-aortic balloon pumping and steroid pulse therapy, along with the discontinuation of pranlukast. It is recommended that careful attention must be paid to signs of a systemic eosinophilic condition or even fulminant eosinophilic myocarditis in asthmatic patients who have begun treatment with antileukotriene drugs following withdrawal of steroids.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11514498      PMCID: PMC1729903          DOI: 10.1136/heart.86.3.e7

Source DB:  PubMed          Journal:  Heart        ISSN: 1355-6037            Impact factor:   5.994


  9 in total

1.  Leukotriene antagonists and Churg-Strauss syndrome: the smoking gun.

Authors:  R G Stirling; K F Chung
Journal:  Thorax       Date:  1999-10       Impact factor: 9.139

2.  Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment.

Authors:  R L Green; A G Vayonis
Journal:  Lancet       Date:  1999-02-27       Impact factor: 79.321

3.  Churg-Strauss syndrome after corticosteroid withdrawal in an asthmatic patient treated with pranlukast.

Authors:  M Kinoshita; T Shiraishi; T Koga; M Ayabe; T Rikimaru; K Oizumi
Journal:  J Allergy Clin Immunol       Date:  1999-03       Impact factor: 10.793

4.  Progressive infiltrates and eosinophilia with multiple possible causes.

Authors:  E B Milbrandt; W Byron; B Davis
Journal:  Chest       Date:  2000-07       Impact factor: 9.410

5.  Pulmonary infiltrates, eosinophilia, and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast.

Authors:  M E Wechsler; E Garpestad; S R Flier; O Kocher; D A Weiland; A J Polito; M M Klinek; T D Bigby; G A Wong; R A Helmers; J M Drazen
Journal:  JAMA       Date:  1998-02-11       Impact factor: 56.272

6.  Churg-Strauss syndrome associated with montelukast therapy.

Authors:  J M Tuggey; H S Hosker
Journal:  Thorax       Date:  2000-09       Impact factor: 9.139

7.  Eosinophilic myocarditis associated with dense deposits of eosinophil cationic protein (ECP) in endomyocardium with high serum ECP.

Authors:  M Arima; T Kanoh
Journal:  Heart       Date:  1999-06       Impact factor: 5.994

8.  The American College of Rheumatology 1990 criteria for the classification of Churg-Strauss syndrome (allergic granulomatosis and angiitis).

Authors:  A T Masi; G G Hunder; J T Lie; B A Michel; D A Bloch; W P Arend; L H Calabrese; S M Edworthy; A S Fauci; R Y Leavitt
Journal:  Arthritis Rheum       Date:  1990-08

9.  Formes frustes of Churg-Strauss syndrome.

Authors:  A Churg; M Brallas; S R Cronin; J Churg
Journal:  Chest       Date:  1995-08       Impact factor: 9.410

  9 in total
  8 in total

1.  Churg-Strauss syndrome and the leukotriene receptor antagonist pranlukast.

Authors:  Junsuke Shimbo; Osamu Onodera; Keiko Tanaka; Shoji Tsuji
Journal:  Clin Rheumatol       Date:  2004-12-02       Impact factor: 2.980

Review 2.  Benefit-risk assessment of antileukotrienes in the management of asthma.

Authors:  Luis García-Marcos; Antje Schuster; Eduardo G Pérez-Yarza
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

3.  Churg-Strauss syndrome (CSS) in a patient receiving pranlukast.

Authors:  Shigeto Kobayashi; Shyugo Ishizuka; Naoto Tamura; Makiyo Takaya; Kazuhiko Kaneda; Hiroshi Hashimoto
Journal:  Clin Rheumatol       Date:  2003-11-04       Impact factor: 2.980

Review 4.  Pranlukast: a review of its use in the management of asthma.

Authors:  Susan J Keam; Katherine A Lyseng-Williamson; Karen L Goa
Journal:  Drugs       Date:  2003       Impact factor: 9.546

5.  The linkage between Churg-Strauss syndrome and leukotriene receptor antagonists: fact or fiction?

Authors:  Deanna L McDanel; Barbara A Muller
Journal:  Ther Clin Risk Manag       Date:  2005-06       Impact factor: 2.423

Review 6.  A case report and literature review of Churg-Strauss syndrome presenting with myocarditis.

Authors:  Lu Qiao; Dengfeng Gao
Journal:  Medicine (Baltimore)       Date:  2016-12       Impact factor: 1.889

7.  The Diagnostic Challenge of Eosinophilic Granulomatosis With Polyangiitis Presenting as Acute Eosinophilic Myocarditis: Case Report and Literature Review.

Authors:  Hiroyuki Yamamoto; Katsuya Hashimoto; Yoshihiko Ikeda; Jun Isogai; Toru Hashimoto
Journal:  Front Cardiovasc Med       Date:  2022-07-07

8.  Churg-Strauss syndrome presenting with massive pericardial effusion.

Authors:  Shinro Matsuo; Yuichi Sato; Tetsuya Matsumoto; Nobu Naiki; Minoru Horie
Journal:  Heart Vessels       Date:  2007-03-23       Impact factor: 1.814

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.